The treatment of Multiple Myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited believe in immune-based anti-MM therapy due to the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies are the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment and vision for MM immunotherapy in the short- and mid-term future.

This content is only available as a PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.